CA-XSOLLA/PAYTM-INDIA
27.1.2022 08:58:04 CET | Business Wire | Press release
Xsolla, the video game business engine that helps developers and publishers launch and operate games globally, today announced it teamed up with Paytm Payment Gateway, India's leading payments solutions provider, to bring gaming payments solutions to India.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126006130/en/
Xsolla integrated Paytm’s Digital Wallet, Unified Payment Interface (UPI), and online banking payment solutions into its Pay Station platform. Video game developers and publishers can monetize their products in India giving them access to the massive gaming marketplace of more than 400 million gamers, second only to China’s playerbase.
“India has become one of the fastest-growing game economies in Asia, bringing in approximately $1.5B annually, with growth expected to nearly triple by 2024,” said Xsolla’s Head of Payments and Commerce, Anton Zelenin. “Historically, India’s payments market has been dominated by cash, and is only now evolving to meet the demands of its increasingly smartphone-led online shopping culture. To sell successfully in this country, developers need access to multiple payment methods which can be complicated. This is where Xsolla brings value with our payment solutions to interface with pre-integrated local payment methods.”
“We are happy to partner with a global brand like Xsolla,” said Praveen Sharma, Sr. Vice President - Paytm. “The gaming industry in India has been on the upward growth trajectory over the past few years, and this is a trend that will continue in the coming times. The solutions that Xsolla is providing to the industry are path-breaking and we’re proud to be their payments partner in this journey.”
Any merchant seeking to sell in India requires a local entity and local bank account. The integration with Paytm Payment Gateway establishes Xsolla as the merchant of record for its clients, enabling them to bypass the time-consuming process. Xsolla is one of a select few services to offer India local payments for cross-border clients.
To learn more about Xsolla Pay Station offerings visit: https://xsolla.pro/xps
To learn more about the gaming economy in India, download our ebook at: https://xsolla.pro/ieb
About Xsolla
Xsolla is the world's leading video game commerce company, with a robust and powerful set of tools and services designed specifically for the games industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes to promote and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla continues to solve the inherent complexities of global distribution, marketing, and monetization so their partners can grow audience, engagement, and revenue. With offices worldwide, Xsolla currently works with major gaming entities like Valve, Twitch, Roblox, Ubisoft, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more. For additional information, please visit xsolla.com.
Xsolla - Accelerate Your Video Game Commerce - https://xsolla.pro/agc
About Paytm
Paytm is India's leading financial services company that offers full-stack payments & financial solutions to consumers, offline merchants and online platforms. The company is on a mission to bring half a billion Indians into the mainstream economy through payments, commerce, banking, investments, and financial services. One97 Communications Limited that owns the brand Paytm is founded by Vijay Shekhar Sharma and is headquartered in Noida, Uttar Pradesh. Its investors include Softbank, Ant Financial, AGH Holdings, SAIF Partners, Berkshire Hathaway, T Rowe Price, and Discovery Capital.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220126006130/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom